首页> 美国卫生研究院文献>PLoS Neglected Tropical Diseases >Unravelling the rate of action of hits in the Leishmania donovani box using standard drugs amphotericin B and miltefosine
【2h】

Unravelling the rate of action of hits in the Leishmania donovani box using standard drugs amphotericin B and miltefosine

机译:使用标准药物两性霉素B和米替福辛阐明利什曼原虫多发性中框的命中率

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In recent years, the neglected diseases drug discovery community has elected phenotypic screening as the key approach for the identification of novel hit compounds. However, when this approach is applied, important questions related to the mode of action for these compounds remain unanswered. One of such questions is related to the rate of action, a useful piece of information when facing the challenge of prioritising the most promising hit compounds. In the present work, compounds of the “Leishmania donovani box” were evaluated using a rate of action assay adapted from a replicative intracellular high content assay recently developed. The potency of each compound was determined every 24 hours up to 96 hours, and standard drugs amphotericin B and miltefosine were used as references to group these compounds according to their rate of action. Independently of this biological assessment, compounds were also clustered according to their minimal chemical scaffold. Comparison of the results showed a complete correlation between the chemical scaffold and the biological group for the vast majority of compounds, demonstrating how the assay was able to bring information on the rate of action for each chemical series, a property directly linked to the mode of action. Overall, the assay here described permitted us to evaluate the rate of action of the “Leishmania donovani box” using two of the currently available drugs as references and, also, to propose a number of fast-acting chemical scaffolds present in the box as starting points for future drug discovery projects to the wider scientific community. The results here presented validate the use of this assay for the determination of the rate of action early in the discovery process, to assist in the prioritisation of hit compounds.
机译:近年来,被忽视的疾病药物发现界已选择表型筛选作为鉴定新型命中化合物的关键方法。但是,当采用这种方法时,与这些化合物的作用方式有关的重要问题仍未得到解答。其中一个问题与作用速度有关,这是在面临对最有前景的命中化合物进行优先排序的挑战时的有用信息。在目前的工作中,使用从最近开发的复制性细胞内高含量测定法改编的作用速率测定法评估“利什曼原虫多诺万尼盒”的化合物。每24小时至96小时确定每种化合物的效价,并使用标准药物两性霉素B和米替福辛作为参照,根据其作用速率对这些化合物进行分组。独立于该生物学评估,化合物也根据其最小化学支架聚集。结果比较表明,绝大多数化合物的化学支架与生物学组之间具有完全相关性,这表明该测定法如何能够带来有关每个化学系列的作用速率的信息,该特性直接与化合物的模式有关。行动。总体而言,此处描述的测定方法使我们能够使用两种当前可用的药物作为参考来评估“利什曼原虫多诺万尼盒子”的作用速率,并且还提出了盒子中存在的多种速效化学支架作为开始面向更广泛的科学界的未来药物发现项目的要点。此处提供的结果验证了此测定法在发现过程早期确定作用速率中的用途,以帮助确定命中化合物的优先级。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号